Trials / Completed
CompletedNCT00166413
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months. If their disease worsens or does not improve during that time frame dexamethasone will be added to the treatment program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 | 40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-12-01
- First posted
- 2005-09-14
- Last updated
- 2011-05-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00166413. Inclusion in this directory is not an endorsement.